Skip to main content
Erschienen in: European Journal of Medical Research 1/2023

Open Access 01.12.2023 | Research

Percutaneous coronary intervention vs. coronary artery bypass grafting in emergency and non-emergency unprotected left-main revascularization

verfasst von: Amin Daoulah, Abdulrahman H. Alqahtani, Ahmed Elmahrouk, Nooraldaem Yousif, Wael Almahmeed, Amr A. Arafat, Turki Al Garni, Mohammed A. Qutub, Ziad Dahdouh, Mohammed Alshehri, Ahmad S. Hersi, Majed M. Malak, Syifa R. Djunaedi, Ayesha Zaidi, Maryam Jameel Naser, Wael Qenawi, Abdelmaksoud Elganady, Taher Hassan, Vincent Ball, Youssef Elmahrouk, Adnan Fathey Hussien, Badr Alzahrani, Reda Abuelatta, Ehab Selim, Ahmed Jamjoom, Khalid Z. Alshali, Shahrukh Hashmani, Wael Refaat, Hameedullah M. Kazim, Mohamed Ajaz Ghani, Haitham Amin, Ahmed M. Ibrahim, Abdulwali Abohasan, Mohamed N. Alama, Mohammed Balghith, Ibrahim A. M. Abdulhabeeb, Osama Ahmad, Mohamed Ramadan, Ahmed A. Ghonim, Abeer M. Shawky, Husam A. Noor, Abdulrahman M. Alqahtani, Faisal Al Samadi, Seraj Abualnaja, Rasha Taha Baqais, Abdulkarim Alhassoun, Issam Altnji, Mushira Khan, Abdulaziz Alasmari, Alwaleed Aljohar, Niranjan Hiremath, Jairam Aithal, Amir Lotfi

Erschienen in: European Journal of Medical Research | Ausgabe 1/2023

Abstract

Background

The optimal revascularization strategy in patients with left main coronary artery (LMCA) disease in the emergency setting is still controversial. Thus, we aimed to compare the outcomes of percutaneous coronary interventions (PCI) vs. coronary artery bypass grafting (CABG) in patients with and without emergent LMCA disease.

Methods

This retrospective cohort study included 2138 patients recruited from 14 centers between 2015 and 2019. We compared patients with emergent LMCA revascularization who underwent PCI (n = 264) to patients who underwent CABG (n = 196) and patients with non-emergent LMCA revascularization with PCI (n = 958) to those who underwent CABG (n = 720). The study outcomes were in-hospital and follow-up all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE).

Results

Emergency PCI patients were older and had a significantly higher prevalence of chronic kidney disease, lower ejection fraction, and higher EuroSCORE than CABG patients. CABG patients had significantly higher SYNTAX scores, multivessel disease, and ostial lesions. In patients presenting with arrest, PCI had significantly lower MACCE (P = 0.017) and in-hospital mortality (P = 0.016) than CABG. In non-emergent revascularization, PCI was associated with lower MACCE in patients with low (P = 0.015) and intermediate (P < 0.001) EuroSCORE. PCI was associated with lower MACCE in patients with low (P = 0.002) and intermediate (P = 0.008) SYNTAX scores. In non-emergent revascularization, PCI was associated with reduced hospital mortality in patients with intermediate (P = 0.001) and high (P = 0.002) EuroSCORE compared to CABG. PCI was associated with lower hospital mortality in patients with low (P = 0.031) and intermediate (P = 0.001) SYNTAX scores. At a median follow-up time of 20 months (IQR: 10–37), emergency PCI had lower MACCE compared to CABG [HR: 0.30 (95% CI 0.14–0.66), P < 0.003], with no significant difference in all-cause mortality between emergency PCI and CABG [HR: 1.18 (95% CI 0.23–6.08), P = 0.845].

Conclusions

PCI could be advantageous over CABG in revascularizing LMCA disease in emergencies. PCI could be preferred for revascularization of non-emergent LMCA in patients with intermediate EuroSCORE and low and intermediate SYNTAX scores.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
LMCA
Left-main coronary artery
PCI
Percutaneous coronary intervention
CABG
Coronary artery bypass graft surgery
MACCE
Major adverse cardiovascular and cerebrovascular events
EuroSCORE score
European system for cardiac operative risk evaluation
CABG
Coronary artery bypass grafting
MACCE
Major adverse cardiovascular and cerebrovascular events
OR
Odds ratio
CI
Confidence interval
IQR
Interquartile range
HR
Hazard ratio
LV
Left ventricle
CAD
Coronary artery disease
EHR
Electronic health record
VIF
Variance inflation factor
EuroSCORE score
European system for cardiac operative risk evaluation
NSTE-ACS
Non-ST Elevation Acute Coronary Syndrome
SYNTAX
The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery
DES
Drug eluting stent
ACE
Angiotensin-converting enzyme
ARB
Angiotensin II receptor blocker
ASA
Aspirin

Background

Left main coronary artery (LMCA) disease represents a highly morbid condition with a poor prognosis if not revascularized [1]. Furthermore, infarction related to LMCA disease is associated with a high myocardial jeopardy score and extensive ischemia to multiple large coronary territories. It, therefore, carries an increased risk of complications, including left ventricular (LV) systolic dysfunction, cardiogenic shock, and death [2]. Historically, revascularization with coronary artery bypass grafting (CABG) has been the gold standard for LMCA disease in stable coronary artery disease (CAD). With current stent technology and guideline-based acute coronary syndrome (ACS) management, percutaneous coronary intervention (PCI) revascularization for the left-main disease is now considered non-inferior to CABG in patients with stable CAD and low to intermediate SYNTAX scores [2, 3]. Published reports indicated that patients undergoing PCI revascularization for unprotected LMCA disease are increasing, and CABG procedures are decreasing [4].
The number of patients with LMCA disease and high anatomical complexity included in randomized controlled trials is low because they are usually excluded [5]. Consequently, the risk estimates and confidence intervals are imprecise; however, they suggest a trend toward better survival with CABG [3]. There is a paucity of data to guide left-main revascularization in emergency presentations, including cardiac arrest and cardiogenic shock complicating acute myocardial infarction. The optimal revascularization strategies in emergent and non-emergent LMCA revascularization have not been thoroughly evaluated. Considering this gap in the evidence, we conducted this study to analyze the outcomes of reperfusion strategies (PCI versus CABG) for emergent and non-emergent LMCA disease.

Methods

Study design, patient population

The Gulf left-main registry contains data about LMCA revascularization with either PCI or CABG from 14 cardiac centers in the Gulf Area [6, 7]. Patients were recruited from January 2015 to December 2019. A total of 2657 patients with significant LMCA disease were identified. The registry included 2138 patients with unprotected left-main coronary artery (ULMCA) disease; 460 had emergent, and 1678 had non-emergent revascularization. We compared patients with emergent LMCA disease who had PCI (n = 264) to CABG patients (n = 196) and patients with non-emergent LMCA who had PCI (n = 958) to those who had CABG (n = 720). We excluded patients with previous LMCA PCI (n = 37), Unprotected LMCA treated medically (n = 193), concomitant valvular or aortic surgery (n = 115), and those with protected LMCA disease with patent grafts (n = 174).

Definitions

The emergent LMCA revascularization group included all ST-elevation myocardial infarction (STEMI) cases and high-risk non-ST-elevation acute coronary syndrome (NSTE-ACS). High-risk NSTE-ACS included patients in cardiac arrest and/or cardiogenic shock. The non-emergent LMCA revascularization group included all remaining patients who underwent LMCA revascularization.
Significant LMCA disease was defined as luminal stenosis greater than 50%.
Unprotected LMCA disease was defined as LMCA disease without previous bypass grafts to either the left anterior descending (LAD) or circumflex coronary artery.
Preprocedural patient risk stratification was performed using the European System for Cardiac Operative Risk Evaluation (EuroSCORE II) [8]. The EuroSCORE II is divided into three categories [low score (0–2), medium (3–5) and high (≥ 6)].
The SYNTAX score was used to score the angiographic lesions [9]. The SYNTAX score was divided into three groups [low score (≤ 22), intermediate (23–32), and high (> 33)].
Medina classification was used for LM bifurcation lesions [10].
Bleeding events were defined according to the International Society of Thrombosis and Hemostasis (ISTH) Scientific and Standardization Committee's (SSC) statement [11, 12].

Clinical assessment and clinical follow-up

The data pertaining to the patient's demographics, presentation, medications at the time of discharge, and in-patient and follow-up outcomes were analyzed in both emergent and non-emergent LMCA revascularization procedures. Clinical outcomes included hospital and follow-up all-cause mortality and major adverse cardiac and cerebrovascular events (MACCEs). MACCEs included the composite endpoint of myocardial infarction (MI), cerebrovascular events, target lesion revascularization, target vessel revascularization, and cardiac or noncardiac mortality. The mechanism by which follow-up events were recorded was based either on ICD coding diagnosis or on clinical description based on clinical diagnosis by admitting physicians in the electronic health record (EHR).

Ethical approval

This study was approved by the Institutional Review Board of King Faisal Specialist Hospital and Research Center in Riyadh (12-November 2020—RAC # 2201226: Gulf-LM Registry) and was carried out per local guidelines and ethical guidelines of the Declaration of Helsinki [13]. The IRB waived informed consent for this study due to its retrospective and observational nature and the absence of any patient-identifying information.

Statistical analysis

Stata 17 (Stata Corp- College Station- TX- USA) was used for all analyses. Quantitative data were evaluated for normality distribution using the Shapiro‒Wilk test, and normally distributed variables were compared using the Student t-test and presented as the mean and standard deviation. Skewed quantitative data were expressed as the median (interquartile range) and compared with the Wilcoxon test. Qualitative data were expressed as numbers and percentages and compared with the Chi-squared or Fisher's exact test if the expected frequency was less than five. The distribution of time-to-event outcomes (MACCE and survival) was plotted using Kaplan‒Meier curves and compared with the log-rank test. Multivariable logistic regression analysis was used to evaluate factors associated with hospital MACCE and mortality in both emergent and non-emergent LMCA revascularization separately. Data were grouped into four models; baseline data, presentations, EuroSCORE, and SYNTAX score. Univariable logistic regression analysis was performed, and all variables were included in a stepwise forward selection regression model. Significant variables were retained in the final model. The interaction between PCI/CABG and presentation, EuroSCORE, or SYNTAX score was evaluated. The odds ratio and its 95% confidence interval, and P-values were reported. Collinearity was tested with the variance inflation factor (VIF), and all variables included in the model had VIF < 1.5. Multivariable Cox regression analysis was used to evaluate factors associated with the time-to-event outcomes (MACCE and survival). Stepwise forward selection was used, and a P < 0.05 was used to retain the variables in the final model. The model contained all patients with emergent and non-emergent LMCA revascularization, and the interaction between emergent/non-emergent revascularization and the technique (PCI vs. CABG) was evaluated in the final model. All preoperative and angiographic variables were included. The hazard ratio and its 95% confidence interval and P-value were reported. A P-value of less than 0.05 was considered statistically significant.

Results

Preprocedural and procedural technique and lesion characteristics

In the emergent LMCA revascularization group, patients who underwent PCI were older and had a significantly higher prevalence of chronic kidney disease than those who underwent CABG. Peripheral arterial disease was more common in patients with non-emergent PCI than non-emergent CABG. The EuroSCORE II was significantly higher in patients with PCI than those with CABG (Table 1).
Table 1
Comparison of the baseline demographics between patients who had emergency left main (LM) and non-emergency LM revascularization
 
Overall, n = 2138
Emergent LM revascularization n = 460 (21.5%)
P-Value
Non-emergent LM revascularization n = 1678 (78.5%)
P Value
PCI (n = 264)
CABG (n = 196)
PCI (n = 958)
CABG (n = 720)
Baseline characteristics
 Age (years), median (IQR)
64 (57–70)
63 (56–72)
60 (54- 68)
0.004
66 (60–72)
62 (55–69)
 < 0.001
 Body mass index (kg/m2), median (IQR)
28 (25- 32)
28 (25–31)
28 (25–30)
0.269
29 (26–33)
28 (25–31)
 < 0.001
 Gender (male), n (%)
1678 (78.5%)
202 (76.52%)
170 (86.73%)
0.006
692 (7223%)
614 (85.28%)
 < 0.001
 Smoker, n (%)
849 (39.7%)
85 (32.20%)
83 (42.35%)
0.025
394 (41.13%)
287 (39.86%)
0.601
 Diabetes mellitus, n (%)
1468 (68.7%)
185 (70.08%)
139 (70.92%)
0.845
619 (64.61%)
525 (72.92%)
 < 0.001
 Hypertension, n (%)
1495 (70.4%)
173 (65.78%)
122 (62.24%)
0.434
686 (72.67%)
514 (71.39%)
0.564
 Dyslipidemia, n (%)
1463 (69.0%)
179 (68.06%)
125 (63.78%)
0.337
642 (68.15%)
517 (71.81%)
0.108
 Congestive heart failure, n (%)
261 (12.2%)
44 (16.67%)
23 (11.73%)
0.138
152 (15.87%)
42 (5.83%)
 < 0.001
 Peripheral arterial disease, n (%)
246 (11.5%)
28 (10.61%)
20 (10.20%)
0.889
156 (16.28%)
42 (5.83%)
 < 0.001
 Cerebral vascular accident, n (%)
222 (10.4%)
30 (11.36%)
11 (5.61%)
0.032
149 (15.55%)
32 (4.44%)
 < 0.001
 Chronic kidney disease, n (%)
437 (20.4%)
62 (23.48%)
29 (14.80%)
0.021
254 (26.51%)
92 (12.78%)
 < 0.001
 Atrial fibrillation, n (%)
183 (8.6%)
27 (10.23%)
12 (6.12%)
0.118
127 (13.26%)
17 (2.36%)
 < 0.001
 Previous myocardial infarction, n (%)
613 (28.7%)
84 (31.82%)
60 (30.61%)
0.783
334 (34.86%)
135 (18.75%)
 < 0.001
 EuroSCORE, median (IQR)
2.9 (1.26–4.56)
3.9 (2.01–7)
2.45 (1.27–5)
 < 0.001
1.75 (1.04–3.65)
3.65 (1.6–4.65)
 < 0.001
CABG: coronary artery bypass graft surgery, PCI: percutaneous coronary intervention, EuroSCORE score: European system for cardiac operative risk evaluation, IQR: interquartile range
Eighteen patients (1%) presented with cardiac arrest (50% ventricular fibrillation), 82 (3.8%) with cardiogenic shock, and 52 (2.4%) with both. Ninety-five percent of cardiac arrests occurred in-hospital, and 95% of cardiogenic shocks occurred pre-revascularization. More patients in cardiogenic shock and cardiac arrest had PCI. Three hundred eighty-nine patients (84.6%) presented with STEMI; 81 (21%) were in cardiogenic shock and cardiac arrest. Seventy-one (15.4%) patients presented with high-risk (arrest and shock) non-ST-elevation acute coronary syndrome (NSTE-ACS). While more patients with STEMI underwent CABG, more patients presenting with NSTE-ACS underwent PCI. Patients who underwent PCI had significantly lower left ventricular ejection fractions than those who underwent CABG (Table 2). The most frequently observed anatomical pattern was Medina 1,1,1 lesion (35.5%), followed by 1,1,0 (18.8%). Patients who underwent CABG had significantly higher SYNTAX scores, multivessel disease, and ostial lesions. However, PCI patients had significantly lower SYNTAX scores and more isolated LMCA disease or LMCA with either single or double-vessel disease and distal bifurcation lesions (Table 3).
Table 2
Comparison of the hospital presentation between patients who had emergency left main (LM) vs. non-emergency LM revascularization
 
Overall, n = 2138
Emergent LM revascularization n = 460 (21.5%)
P-Value
Non-emergent LM revascularization n = 1678 (78.5%)
P Value
PCI (n = 264)
CABG (n = 196)
PCI (n = 958)
CABG (n = 720)
Hospital presentation
 Cardiac arrest, n (%)
18 (1%)
7 (2.65%)
11 (5.61%)
0.105
NA
NA
NA
Types, n (%)
 Ventricular fibrillation
9 (50%)
2 (28.57%)
7 (63.64%)
0.335
NA
NA
NA
 Pulseless electrical activity
6 (33.3%)
3 (42.86%)
3 (27.27%)
0.627
NA
NA
NA
 Asystole
3 (16%)
2 (28.57%)
1 (9.09%)
0.528
NA
NA
NA
Location, n (%)
 Out of hospital cardiac arrest (OHCA)
1 (5.5%)
1 (14.29%)
0
0.389
NA
NA
NA
 In-hospital cardiac arrest (IHCA)
17 (94.5%)
6 (85.71%)
11 (100%)
0.389
NA
NA
NA
Timing, n (%)
 Pre coronary angiography
18 (100%)
7 (100%)
11 (100%)
 > 0.99
NA
NA
NA
 Post coronary angiography
0 (0%)
0
0
 > 0.99
NA
NA
NA
 Cardiogenic shock and cardiac arrest, n (%)
52 (2.4%)
44 (16.67%)
8 (4.08%)
 < 0.001
   
Timing, n (%)
 Pre coronary angiography
47 (90.4%)
43 (97.73%)
4 (50%)
0.001
NA
NA
NA
 Post coronary angiography
5 (9.6%)
1 (2.27%)
4 (50%)
0.001
NA
NA
NA
 Cardiogenic shock, n (%)
82 (3.8%)
57 (21.59%)
25 (12.76%)
0.014
NA
NA
NA
Timing, n (%)
 Pre coronary angiography
78 (95%)
57 (100%)
21 (84%)
0.007
NA
NA
NA
 Post coronary angiography
4 (5%)
0
4 (16%)
0.007
NA
NA
NA
Coronary presentation, n (%)
 ST-elevation myocardial infarction
389 (18.2%)
214 (81.06%)
175 (89.29%)
0.016
NA
NA
NA
 Non-ST-elevation acute coronary syndrome
1084 (50.7%)
50 (18.93%)
21 (10.71%)
0.034
578 (60.33%)
435 (60.41%)
0.868
 Stable coronary artery disease
273 (12.77%)
NA
NA
NA
137 (14.32%)
136 (18.89%)
0.012
 Silent ischemia/others
380 (17.78%)
NA
NA
NA
234 (24.45%)
146 (20.28%)
0.043
 Left ventricular ejection fraction, mean (SD)
44.8 ± 11.6
40 (35–45)
50 (40–55)
 < 0.001
45 (35–55)
50 (40–55)
 < 0.001
 LVEF ≤ 40%, n (%)
578 (27.0%)
98 (37.12%)
33 (16.84%)
 < 0.001
291 (30.38%)
156 (21.67%)
 < 0.001
 LVEF 41–49%, n (%)
618 (28.91%)
101 (38.26%)
48 (24.49%)
0.002
286 (29.85%)
183 (25.42%)
0.045
 LVEF ≥ 50%, n (%)
942 (44.1%)
65 (24.62%)
115 (58.67%)
 < 0.001
381 (39.77%)
381 (52.92%)
 < 0.001
 Creatinine clearance (ml/min), mean (SD)
76.2 ± 24.2
90 (62–90)
83 (65–90)
0.016
90 (53–93)
83 (70–90)
0.002
 Hemoglobin (g/L), median (IQR)
13.4 (12–14.6)
13.4 (12.2–14.6)
13 (11.5–14.5)
0.012
13.6 (12.3–14.9)
13.2 (11.7–14.3)
 < 0.001
SD: standard deviation, CABG: coronary artery bypass graft surgery, PCI: percutaneous coronary intervention,, IQR: interquartile range, LVEF: left ventricular ejection fraction
Table 3
Comparison of the angiographic and procedural data between patients who had emergency left main (LM) vs. non-emergency LM revascularization
 
Overall, n = 2138
Emergent LM revascularization n = 460 (21.5%)
P-Value
Non-emergent LM revascularization n = 1678 (78.5%)
P Value
PCI (n = 264)
CABG (n = 196)
PCI (n = 958)
CABG (n = 720)
Angiographic characteristics
 Medina classification, n (%)
   
 < 0.001
  
 < 0.001
 1,1,1
760 (35.5%)
74 (28.03%)
62 (31.63%)
0.402
356 (37.16%)
268 (37.22%)
0.979
 1,0,1
162 (7.6%)
11 (4.17%)
28 (14.29%)
 < 0.001
37 (3.86%)
86 (11.94%)
 < 0.001
 0,1,1
393 (18.4%)
79 (29.92%)
45 (22.96%)
0.096
153 (15.97%)
116 (16.11%)
0.938
 1,1,0
402 (18.8%)
60 (22.73%)
11 (5.61%)
 < 0.001
250 (26.10%)
81 (11.25%)
 < 0.001
 1,0,0
202 (9.4%)
20 (7.58%)
23 (11.73%)
0.130
96 (10.02%)
81 (11.25%)
0.417
 0,1,0
160 (7.5%)
11 (4.17%)
19 (9.69%)
0.016
45 (4.70%)
85 (11.81%)
 < 0.001
 0,0,1
59 (2.7%)
9 (3.41%)
8 (4.08%)
0.689
21 (2.19%)
21 (2.92%)
0.347
Lesion characteristics
 Isolated left main disease, n (%)
138 (6.5%)
22 (8.3%)
12 (6.1%)
 < 0.001
81 (8.5%)
23 (3.2%)
 < 0.001
 LM + (triple-vessel disease), n (%)
1202 (56.2%)
98 (37.1%)
124 (63.3%)
 < 0.001
481 (50.2%)
499 (69.3%)
 < 0.001
 LM + (LAD and LCx), n (%)
327 (15.3%)
50 (18.9%)
27 (13.8%)
 < 0.001
138 (14.4%)
112 (15.6%)
 < 0.001
 LM + [RCA and (LAD or LCx)], n (%)
139 (6.5%)
20 (7.6%)
25 (12.8%)
 < 0.001
44 (4.6%)
50 (6.9%)
 < 0.001
 LM + LAD, n (%)
287 (13.4%)
63 (23.9%)
8 (4.1%)
 < 0.001
188 (19.6%)
28 (3.9%)
 < 0.001
 LM + LCx, n (%)
35 (1.6%)
10 (3.8%)
0 (0.0%)
 < 0.001
20 (2.1%)
5 (0.7%)
 < 0.001
 LM + RCA, n (%)
10 (0.5%)
1 (0.4%)
0 (0.0%)
0.99
6 (0.6%)
3 (0.4%)
0.740
SYNTAX score
   
 < 0.001
  
 < 0.001
 Low (≤ 22), n (%)
430 (20.2%)
81 (30.68%)
18 (9.18%)
 < 0.001
223 (23.30%)
108 (15.17%)
 < 0.001
 Intermediate (23–32), n (%)
1107 (52.0%)
104 (39.39%)
83 (42.35%)
0.524
577 (60.29%)
343 (48.17%)
 < 0.001
 High (≥ 33), n (%)
592 (27.8%)
79 (29.92%)
95 (48.47%)
 < 0.001
157 (16.41%)
261 (36.66%)
 < 0.001
 SYNTAX score, median (IQR)
28 (24–33)
28 (22–33)
32 (25–37)
 < 0.001
28 (23–32)
29 (25–35)
 < 0.001
Lesion location
 Ostial/shaft only, n (%)
536 (25.1%)
51 (19.32%)
59 (30.10%)
0.007
184 (19.21%)
242 (33.61%)
 < 0.001
 Distal bifurcation, n (%)
1602 (74.9%)
213 (80.68%)
137 (69.90%)
0.007
774 (80.79%)
478 (66.39%)
 < 0.001
Procedure
 Intra-aortic ballon pump, n (%)
200 (9.4%)
62 (23.48%)
52 (26.53%)
0.454
36 (3.76%)
50 (6.94%)
0.003
 Impella, n (%)
14 (0.7%)
6 (2.27%)
1 (0.51%)
0.247
6 (0.63%)
1 (0.14%)
0.250
CABG: coronary artery bypass graft surgery, PCI: percutaneous coronary intervention, LM: left main, LAD: left anterior descending, LCX: left circumflex, RCA: right coronary, SYNTAX: The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery, IQR: interquartile range

Procedural technique

All PCIs were performed using second-generation DESs (drug-eluting stents). The most common type of stent used was the XIENCE family (Abbott Vascular- Santa Clara, CA, USA) of everolimus-eluting coronary stent systems (65%). The most common PCI approach in emergency LMCA revascularization patients was the planned 2-stent strategy (80%). The most frequently performed type of CABG in emergency LMCA revascularization was conventional CABG (on-pump), accounting for 85% of patients. The left internal mammary artery was used in 98%, double mammary arteries in 5%, and radial conduits in 1% of cases, whereas 99% of patients received venous grafts.

Discharge and follow-up medications

In emergent LMCA revascularization, patients who underwent PCI were more frequently discharged on P2Y12, beta-blockers, statins, and ACEi/ARBs (angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers). No difference was seen in either type of revascularization strategy concerning aspirin (ASA) on discharge (Table 4). A similar pattern was observed at follow-up for P2Y12 inhibitors and ACEi/ARBs. ASA was more common in CABG patients than PCI patients (p = 0.032). No difference was observed between PCI and CABG patients concerning beta-blockers or statin prescriptions at discharge (Table 4).
Table 4
Comparison of the medications during discharge and follow-up between patients who had emergency left main (LM) vs. non-emergency LM revascularization
 
Overall, n = 2138
Emergent LM revascularization n = 460 (21.5%)
P-Value
Non-emergent LM revascularization n = 1678 (78.5%)
P Value
PCI (n = 264)
CABG (n = 196)
PCI (n = 958)
CABG (n = 720)
Discharge medications
 ASA, n (%)
2010 (99.10%)
222 (99.55%)
166 (97.65%)
0.095
946 (99.58%)
676 (98.69%)
0.045
 P2Y12 inhibitors, n (%)
1833 (90.40%)
223 (100%)
129 (75.88%)
 < 0.001
946 (99.58%)
535 (78.10%)
 < 0.001
 Beta blocker, n (%)
1914 (94.40%)
216 (96.86%)
146 (85.88%)
 < 0.001
915 (96.32%)
637 (92.99%)
0.003
 Statin, n (%)
1934 (95.40%)
214 (95.96%)
139 (81.76%)
 < 0.001
947 (99.68%)
634 (92.55%)
 < 0.001
 ACE inhibitors or ARB, n (%)
1516 (74.80%)
202 (90.58%)
86 (50.59%)
 < 0.001
847 (89.16%)
381 (55.62%)
 < 0.001
Medications during follow-up
 ASA, n (%)
1713 (97.10%)
174 (96.67%)
135 (100%)
0.032
859 (97.50%)
545 (95.78%)
0.068
 P2Y12 inhibitors, n (%)
1129 (64.00%)
140 (77.78%)
83 (61.48%)
0.002
638 (72.42%)
268 (47.10%)
 < 0.001
 Beta blocker, n (%)
1674 (94.80%)
171 (95.00%)
129 (95.56%)
0.819
838 (95.12%)
536 (94.20%)
0.443
 Statin, n (%)
1727 (97.80%)
174 (96.67%)
130 (96.30%)
0.859
873 (99.09%)
550 (96.66%)
0.001
 ACE inhibitors or ARB, n (%)
1332 (75.50%)
159 (88.33%)
71 (52.59%)
 < 0.001
765 (86.83%)
337 (59.23%)
 < 0.001
ASA: aspirin, ACE: angiotensin-converting enzyme, ARB: angiotensin II receptor blocker, CABG: coronary artery bypass grafting, PCI: percutaneous coronary intervention

In-hospital events

Univariable analysis was used to compare hospital events between PCI and CABG in patients with emergent and non-emergent revascularization. The emergent LMCA revascularization group had higher cardiac mortality (59/460, 12.8%) and total mortality (66/460, 14.35%) without a significant difference between PCI and CABG patients. There was no significant difference between PCI and CABG patients concerning MACCEs. The non-emergent LMCA revascularization group had lower cardiac mortality (22/1678, 1.3%) and total mortality (39/1678, 2.3%). CABG patients reported a higher mortality rate than PCI patients. MACCE and noncardiac mortality were significantly higher in CABG patients than PCI patients. In both the emergent and non-emergent LMCA revascularization groups, hospital stay was significantly longer in CABG patients (Table 5).
Table 5
Comparison of the hospital and follow-up events between patients who had emergency left main (LM) and non-emergency LM revascularization
 
Overall, n = 2138
Emergent LM revascularization n = 460 (21.5%)
P-Value
Non-emergent LM revascularization n = 1678 (78.5%)
P Value
PCI (n = 264)
CABG (n = 196)
PCI (n = 958)
CABG (n = 720)
In-hospital events
 Cardiac death, n (%)
81 (3.8%)
36 (13.64%)
23 (11.73%)
0.546
3 (0.31%)
19 (2.64%)
 < 0.001
 Non-cardiac death, n (%)
24 (1.1%)
4 (1.52%)
3 (1.53%)
 > 0.99
3 (0.31%)
14 (1.94%)
0.001
 Myocardial infarction, n (%)
73 (3.4%)
15 (5.68%)
20 (10.20%)
0.070
3 (0.31%)
35 (4.86%)
 < 0.001
 Target lesion revascularization, n (%)
11 (0.5%)
3 (1.14%)
1 (0.51%)
0.640
2 (0.21%)
5 (0.69%)
0.147
 Target vessel revascularization, n (%)
15 (0.7%)
5 (1.89%)
0
0.075
2 (0.21%)
8 (1.11%)
0.023
 Cerebrovascular events, n (%)
48 (2.2%)
12 (4.55%)
13 (6.63%)
0.329
7 (0.73%)
16 (2.22%)
0.009
 MACCE, n (%)
125 (5.8%)
38 (14.39%)
28 (14.29%)
0.974
16 (1.67%)
43 (5.97%)
 < 0.001
 Congestive heart failure, n (%)
89 (4.2%)
17 (6.44%)
32 (16.33%)
0.001
32 (3.34%)
8 (1.11%)
0.003
 Major bleeding, n (%)
313 (14.6%)
39 (14.77%)
34 (17.35%)
0.455
125 (13.06%)
115 (15.97%)
0.092
 Minor bleeding, n (%)
157 (7.3%)
17 (6.44%)
18 (9.18%)
0.272
50 (5.22%)
72 (10%)
 < 0.001
 Total mortality, n (%)
105 (4.9%)
40 (15.15%)
26 (13.27%)
0.568
6 (0.63%)
33 (4.58%)
 < 0.001
 Duration of hospital stay, median (IQR) (Days)
7 (3–12)
5 (3–9)
13 (9–17)
 < 0.001
3 (0–5)
11 (8–15)
 < 0.001
Follow-up events
 Cardiac death, n (%)
14 (0.7%)
5 (2.59%)
2 (1.23%)
0.889
3 (0.33%)
4 (0.60%)
0.524
 Non-cardiac death, n (%)
25 (1.3%)
2 (1.04%)
0
0.237
10 (1.09%)
13 (1.94%)
0.043
 Myocardial infarction, n (%)
50 (2.6%)
3 (1.63%)
10 (6.29%)
0.005
21 (2.33%)
16 (2.41%)
0.665
 Target lesion revascularization, n (%)
52 (2.72%)
8 (4.35%)
8 (5.03%)
0.371
27 (2.99%)
9 (1.35%)
0.141
 Target vessel revascularization, n (%)
57 (2.98%)
4 (2.17%)
8 (5.03%)
0.046
27 (2.99%)
18 (2.71%)
0.936
 Cerebrovascular events, n (%)
29 (1.64%)
4 (2.22%)
4 (2.96%)
0.636
11 (1.25%)
10 (1.76%)
0.465
 MACCE, n (%)
108 (6.1%)
15 (8.33%)
16 (11.85%)
0.099
48 (5.45%)
29 (5.09%)
0.955
 Congestive heart failure, n (%)
415 (19.4%)
83 (31.44%)
24 (12.24%)
0.008
212 (22.13%)
96 (13.33%)
 < 0.001
 Major bleeding, n (%)
7 (0.4%)
0
0
 
5 (0.57%)
2 (0.35%)
0.614
 Minor bleeding, n (%)
31 (1.76%)
5 (2.78%)
4 (2.96%)
0.685
11 (1.25%)
11 (1.93%)
0.322
 Total mortality, n (%)
39 (2.0%)
7 (3.63%)
2 (1.23%)
0.470
13 (1.41%)
17 (2.54%)
0.036
 Median follow-up time (IQR) (months)
20 (10–37)
20 (13–31)
12 (3–33)
0.002
21 (12–39)
19 (9–37)
0.009
CABG: coronary artery bypass grafting, IQR: interquartile range, MACCE: major adverse cardiovascular and cerebrovascular events, PCI: percutaneous coronary intervention

Follow-up events

The median follow-up time was 20 months (IQR: 10–37 months). Those with emergent LMCA revascularization had a cardiac mortality of 7/460 (1.5%) and a total mortality of 9/460 (1.96%), without a significant difference between PCI and CABG. MACCEs were reported in 31/460 (6.74%) patients, with no significant difference between PCI and CABG. Follow-up myocardial infarction and target vessel revascularization were significantly higher in patients who underwent CABG than in those who underwent PCI. Congestive heart failure was significantly higher in PCI patients than in CABG patients. The non-emergent LMCA revascularization patients had a total mortality of 30/1678 (1.79%), noncardiac (1.37%), and cardiac (0.42%). The total mortality was significantly higher in CABG patients than in PCI patients. MACCE was reported in 77/1678 (4.6%) patients, with no significant difference between PCI and CABG (Table 5). Kaplan‒Meier curves showed no significant difference between CABG and PCI patients in emergent LMCA revascularization regarding all-cause mortality and MACCE (Figs. 1A, B). Kaplan‒Meier curves showed significantly higher all-cause mortality in non-emergent LMCA revascularization patients who underwent CABG, with no significant difference in MACCE between CABG and PCI (Figs. 1C, D).

Multivariable analysis

Several models were constructed to adjust for risk factors for hospital MACCE and mortality in emergent and non-emergent LMCA revascularization. In patients with emergent LMCA revascularization, MACCE was significantly higher in patients with high EuroSCORE, whether they underwent PCI [OR: 5.13 (95% CI 1.98–13.34); P = 0.001] or CABG [OR: 4.35 (95% CI 1.51–12.57); P = 0.007] compared to patients with low EuroSCORE. However, there was no difference in MACCE according to the revascularization technique after adjusting for EuroSCORE [OR: 0.79 (95% CI 0.45–1.38); P = 0.409]. Different revascularization methods did not significantly affect MACCE in different SYNTAX score categories. In patients presenting with arrest, both PCI [7.64 (3.37–17.35); P < 0.001] and CABG [45.81 (11.29- 185.82); P < 0.001] were associated with significantly higher MACCE compared to other presentations. Additionally, PCI had significantly lower MACCE in patients with arrest than CABG [0.46 (0.24- 0.87); P = 0.017] (Table 6).
Table 6
Univariable and multivariable analysis for factors associated with hospital MACCE in emergency and non-emergency left main revascularization
Hospital MACCE
Univariable
Multivariable
Emergency revascularization
OR (95% CI)
P
OR (95% CI)
P
Baseline characteristics
 Male
1.90 (1.05–3.44)
0.033
 Age
1.02 (0.99–1.04)
0.111
 Body mass index
0.99 (0.93–1.04)
0.642
 Smoking
0.85 (0.49–1.47)
0.561
 Diabetes mellitus
0.96 (0.54–1.69)
0.887
 Dyslipidemia
1.02 (0.59–1.78)
0.936
 Hypertension
1.89 (1.03–3.44)
0.038
 Previous myocardial infarction
1.77 (1.04–3.01)
0.037
 Chronic kidney disease
3.57 (2.04–6.24)
 < 0.001
2.99 (1.62–5.50)
 < 0.001
 Peripheral arterial disease
3.22 (1.63–6.33)
0.001
2.45 (1.17–5.13)
0.017
 Cerebrovascular accident
2.09 (0.97–4.50)
0.059
 Congestive heart failure
3.88 (2.13–7.06)
 < 0.001
2.67 (1.37–5.19)
0.004
 Atrial fibrillation
1.92 (0.85–4.24)
0.109
 Ejection fraction category
1.03 (0.74–1.41)
0.874
 PCI vs. CABG
1.01 (0.60–1.71)
0.974
 EuroSCORE
 EuroSCORE
1.08 (1.04–1.10)
 < 0.001
2.69 (1.82–3.97)
 < 0.001
 PCI vs. CABG
1.01 (0.60–1.71)
0.974
0.79 (0.45–1.38)
0.409
Presentation
 Arrest
4.72 (2.63–8.50)
 < 0.001
2.16 (1.11–4.22)
0.024
 Shock
8.73 (4.87–15.64)
 < 0.001
8.69 (4.47–16.92)
 < 0.001
 STEMI
0.26 (0.14–0.67)
 < 0.001
 NSTEMI
0.24 (0.13–0.44)
 < 0.001
 PCI vs. CABG
1.01 (0.60–1.71)
0.974
0.46 (0.24–0.87)
0.017
SYNTAX score
 SYNTAX score
1.02 (0.99–1.04)
0.158
1.38 (0.95–1.99)
0.091
 PCI vs. CABG
1.01 (0.60–1.71)
0.974
1.14 (0.66–1.96)
0.641
Non–emergency revascularization
Baseline characteristics
 Male
1.20 (0.66–2.19)
0.542
 Age
1.01 (0.98–1.03)
0.553
 Body mass index
0.97 (0.92–1.02)
0.232
 Smoking
0.93 (0.55–1.59)
0.796
 Diabetes mellitus
1.16 (0.65–2.05)
0.618
 Dyslipidemia
2.79 (1.31–5.93)
0.008
2.36 (1.22–5.57)
0.013
 Hypertension
1.68 (0.86–3.27)
0.127
 Previous myocardial infarction
1.23 (0.71–2.15)
0.461
 Chronic kidney disease
1.33 (0.73–2.42)
0.350
 Peripheral arterial disease
1.01 (0.45–2.25)
0.989
 Cerebrovascular accident
0.59 (0.21–1.65)
0.317
 Congestive heart failure
1.59 (0.79–3.19)
0.192
2.36 (1.10–5.04)
0.027
 Atrial fibrillation
 Ejection fraction category
0.80 (0.59–1.08)
0.148
 PCI vs. CABG
0.27 (0.15–0.48)
 < 0.001
0.30 (0.16–0.56)
 < 0.001
EuroSCORE
 EuroSCORE
1.06 (1.02–1.12)
0.005
1.07 (1.03–1.11)
0.001
 PCI vs. CABG
0.27 (0.15–0.48)
 < 0.001
0.25 (0.14–0.45)
 < 0.001
Presentation
 Arrest
 Shock
 STEMI
 NSTEMI
0.62 (0.35–1.11)
0.107
 PCI vs. CABG
0.27 (0.15–0.48)
 < 0.001
SYNTAX score
 SYNTAX score
1.02 (0.99–1.05)
0.117
1.17 (0.79–1.73)
0.444
 PCI vs. CABG
0.27 (0.15–0.48)
 < 0.001
0.27 (0.15–0.50)
 < 0.001
MACCE: major adverse cardiovascular and cerebrovascular events, CABG: coronary artery bypass graft surgery, PCI: percutaneous coronary intervention, EuroSCORE score: European system for cardiac operative risk evaluation, STEMI: ST–segment elevation myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction, OR: odds ratio, CI: confidence interval
In emergent LMCA revascularization, hospital all-cause mortality was significantly higher with PCI [36.78 (4.86–278.48); P < 0.001] and CABG [42.13 (5.35–331.75); P < 0.001] in patients with high EuroSCORE compared to low EuroSCORE. While there was no difference between both approaches after adjusting for EuroSCORE [0.87 (0.49–1.56); P = 0.647]. There was no interaction between PCI/CABG and SYNTAX score categories for their effect on hospital all-cause mortality. Mortality was significantly higher in patients presented with arrest and had CABG [133.09 (28.63- 618.50); P < 0.001] or PCI [4.81 (2.09–11.08); P < 0.001]; however, PCI was associated with lower mortality compared to CABG [0.43 (0.22–0.85); P 0.016] (Table 7).
Table 7
Univariable and multivariable analysis for factors associated with hospital mortality in emergency and non-emergency left main revascularization
Hospital mortality
Univariable
Multivariable
Emergency revascularization
OR (95% CI)
P
OR (95% CI)
P
Baseline characteristics
 Male
1.90 (1.05–3.45)
0.033
 Age
1.04 (1.01–1.06)
0.005
1.04 (1.01–1.07)
0.007
 Body mass index
0.95 (0.89–1.01)
0.108
0.93 (0.87–0.99)
0.038
 Smoking
0.56 (0.31–1.01)
0.052
 Diabetes mellitus
0.88 (0.50–1.54)
0.665
 Dyslipidemia
1.43 (0.80–2.55)
0.230
 Hypertension
2.54 (1.34–4.82)
0.004
2.91 (1.38–6.16)
0.005
 Previous myocardial infarction
1.52 (0.89–2.61)
0.127
 Chronic kidney disease
1.81 (1.001–3.36)
0.05
 Peripheral arterial disease
1.93 (0.93–4.01)
0.078
 Cerebrovascular accident
2.09 (0.97–4.50)
0.059
 Congestive heart failure
2.91 (1.58–5.38)
0.001
3.03 (1.50–6.14)
0.002
 Atrial fibrillation
1.62 (071–3.69)
0.255
 Ejection fraction category
1.43 (1.02–2.00)
0.036
2.68 (1.47–4.89)
0.001
 PCI vs. CABG
1.17 (0.69–1.99)
0.568
EuroSCORE
 EuroSCORE
1.09 (1.06–1.13)
 < 0.001
4.45 (2.83–7.01)
 < 0.001
 PCI vs. CABG
1.17 (0.69–1.99)
0.568
0.87 (0.49–1.56)
0.647
Presentation
 Arrest
10.57 (5.84–19.20)
 < 0.001
5.40 (2.77–10.56)
 < 0.001
 Shock
11.53 (6.25–21.27)
 < 0.001
9.07 (4.47 (18.42)
 < 0.001
 STEMI
0.20 (0.11–0.36)
 < 0.001
 NSTEMI
0.21 (0.12–0.39)
 < 0.001
 PCI vs. CABG
1.17 (0.69–1.99)
0.568
0.43 (0.22–0.85)
0.016
SYNTAX score
 SYNTAX score
1.01 (0.98–1.04)
0.044
1.36 (0.94–1.97)
0.099
 PCI vs. CABG
1.17 (0.69–1.99)
0.568
1.31 (0.76–2.28)
0.331
Non–emergency revascularization
 Baseline characteristics
  Male
0.90 (0.411–1.98)
0.800
  Age
1.02 (0.99–1.06)
0.168
1.04 (1.003–1.08)
0.031
  Body mass index
0.96 (0.90–1.03)
0.287
  Smoking
0.64 (0.32–1.28)
0.209
  Diabetes mellitus
1.57 (0.74–3.33)
0.241
  Dyslipidemia
3.88 (1.37–10.99)
0.011
3.56 (1.24–10.22)
0.018
  Hypertension
1.79 (0.78–4.08)
0.167
  Previous myocardial infarction
1.01 (0.50–2.05)
0.973
  Chronic kidney disease
2.77 (1.45–5.30)
0.002
3.74 (1.83–7.62)
 < 0.001
  Peripheral arterial disease
1.37 (0.57–3.31)
0.485
  Cerebrovascular accident
0.44 (0.11–1.84)
0.262
  Congestive heart failure
2.01 (0.91–4.45)
0.083
  Atrial fibrillation
0.57 (0.14–2.39)
0.441
  Ejection fraction category
1.07 (0.72–1.57)
0.743
  PCI vs. CABG
0.13 (0.05–0.32)
 < 0.001
0.100 (0.04–0.25)
 < 0.001
EuroSCORE
 EuroSCORE
1.12 (1.08–1.17)
 < 0.001
1.13 (1.08–1.18)
 < 0.001
 PCI vs. CABG
0.13 (0.05–0.32)
 < 0.001
0.11 (0.04–0.27)
 < 0.001
Presentation
 Arrest
 Shock
 STEMI
 NSTEMI
0.53 (0.26–1.10)
0.089
 PCI vs. CABG
0.13 (0.05–0.32)
 < 0.001
0.13 (0.05–0.32)
 < 0.001
SYNTAX score
 SYNTAX score
1.05 (1.01–1.08)
0.005
1.38 (0.84–2.25)
0.201
 PCI vs. CABG
0.13 (0.05–0.32)
 < 0.001
0.14 (0.06–0.36)
 < 0.001
CABG: coronary artery bypass graft surgery, PCI: percutaneous coronary intervention, EuroSCORE score: European system for cardiac operative risk evaluation, STEMI: ST–segment elevation myocardial infarction; NSTEMI: non-ST-segment elevation myocardial infarction, OR: odds ratio, CI: confidence interval
In non-emergent revascularization, PCI was associated with lower MACCE in patients with low [0.16 (0.04–0.70); P = 0.015] and intermediate [0.20 (0.09–0.48); P < 0.001] EuroSCORE compared to CABG in patients with the same EuroSCORE category. PCI was associated with lower MACCE in patients with low [0.09 (0.02–0.41); P = 0.002] and intermediate [0.30 (0.13–0.73); P = 0.008] SYNTAX scores compared to CABG with the same SYNTAX score category (Table 6).
In non-emergent revascularization, PCI was associated with reduced hospital mortality in patients with intermediate [0.12 (0.03–0.43); P = 0.001] and high [0.13 (0.03–0.47); P = 0.002] EuroSCORE compared to CABG with the same EuroSCORE category. PCI was associated with lower hospital mortality in patients with low [0.09 (0.01–0.89); P = 0.031] and intermediate [0.09 (0.02–0.39); P = 0.001] SYNTAX scores compared to CABG with the same SYNTAX score category (Table 7).
Multivariable Cox regression analysis revealed that factors that increased the follow-up MACCE were female sex, cardiac arrest, cardiogenic shock at presentation, low left ventricular ejection fraction, hypertension, and low body mass index. Emergent PCI had a lower rate of follow-up MACCE compared to CABG [HR: 0.30 (95% CI 0.14–0.66), P < 0.003], with no difference between elective CABG and PCI [HR: 0.79 (95% CI 0.47–1.31), P = 0.355]. Factors associated with follow-up mortality were age, hypertension, peripheral arterial disease, and high EuroSCORE II. There was no difference in follow-up mortality between emergency PCI and CABG [HR: 1.18 (95% CI 0.23- 6.08), P = 0.845]. However, elective PCI was associated with lower follow-up mortality than CABG [HR: 0.35 (95% CI 0.16–0.76), P = 0.008] (Table 8).
Table 8
Multivariable Cox regression analysis for factors affecting follow-up MACCE and all-cause mortality
 
HR (95% CI)
P
Follow-up MACCE
 Female
2.47 (1.58–3.87)
 < 0.001
 Arrest
2.82 (1.06–7.49)
0.038
 Ejection fraction
0.97 (0.95–0.98)
 < 0.001
 Hypertension
2.04 (1.16–3.58)
0.013
 Body mass index
0.95 (0.91–0.99)
0.020
Group
 Elective PCI vs. CABG
0.79 (0.47–1.31)
0.355
 Emergency PCI vs. CABG
0.30 (0.14–0.66)
0.003
Follow-up all-cause mortality
 Age
1.04 (1.004–1.07)
0.027
 Hypertension
5.32 (1.26–22.45)
0.023
 Peripheral arterial disease
2.91 (1.30–6.53)
0.010
 EuroSCORE
1.07 (1.04–1.11)
 < 0.001
Group
 Elective PCI vs. CABG
0.35 (0.16–0.76)
0.008
 Emergency PCI vs. CABG
1.18 (0.23–6.08)
0.845
MACCE: major adverse cardiovascular and cerebrovascular events, CABG: coronary artery bypass graft surgery, PCI: percutaneous coronary intervention, EuroSCORE score: European system for cardiac operative risk evaluation, HR: hazard ratio

Discussion

Several studies addressing revascularization of the LMCA disease focused on patients with chronic coronary artery disease; however, around 7% of patients with LMCA disease present with acute coronary syndrome [14]. Those patients are usually excluded from clinical studies; therefore, it is essential to evaluate the optimal revascularization strategy for LMCA disease in both elective and emergency situations [15]. The Gulf Left-Main Study investigated emergent LMCA revascularization and compared the outcomes of PCI versus CABG. The study found that PCI was associated with lower hospital MACCE and hospital all-cause mortality compared to CABG in patients presented with arrest or shock; however, there was no advantage of PCI vs. CABG in emergency revascularization if stratified by EuroSCORE or SYNTAX score. Additionally, PCI had lower follow-up MACCE compared to CABG in emergent LMCA revascularization within a 20-month follow-up period. PCI was more advantageous than CABG in non-emergency situations, especially in patients with low and intermediate EuroSCORE and SYNTAX scores. Despite being associated with high mortality, revascularization in the acute phase has been shown to improve prognosis [16].
The baseline characteristics differed between groups. The EuroSCORE II was significantly higher in patients with PCI compared to CABG in patients who had emergency revascularization, and there was a greater number of patients with left ventricular ejection fraction (LVEF) of less than 40% in the PCI group in emergency and non-emergency revascularization. However, EuroSCORE was higher in CABG patients with non-emergent revascularization than in PCI. Of patients who required LMCA revascularization, 21.5% were identified as needing revascularization emergently. The study also found that the incidence of LMCA being the culprit lesion in patients with acute myocardial infarction was 5%, which is consistent with a previous report [17, 18].
In a meta-analysis of 977 patients from 13 different studies, the thirty-day mortality was 15% post-emergent LMCA PCI, comparable to the data for the PCI group in this study [19]. In patients who required emergent LMCA revascularization using CABG, the estimated death rate was reported to be 19%, which is higher than the rate of 11.7% in this study, indicating a trend toward percutaneous revascularization for high-risk patients and considering surgical options only for lower-risk selected patients [20]. The choice of revascularization strategy is largely affected by the clinical status of the patients. Urgent revascularization with either PCI or CABG is essential in clinically unstable patients to improve survival [21]. Practically, PCI is more convenient in emergencies. We found that PCI had survival benefits and lower hospital and follow-up MACCE in patients with shock or cardiac arrest. The outcomes of emergency revascularization were affected by patients' characteristics rather than the revascularization technique, except in critically ill patients with either arrest or shock. Optimizing patients before PCI and the early use of mechanical circulatory support in those patients might improve the outcomes of emergency revascularization [22]. In this study, PCI was more advantageous for revascularizing non-emergent LMCA disease, especially in patients with low and intermediate risk stratification using EuroSCORE and SYNTAX scores.
Once discharged, the reported mortality in this study was low (1.23–2.59% CABG vs. PCI, respectively) compared to published reports of 10.5% mortality at one year with emergent PCI of LMCA lesions [23]. This study is the largest series to date to assess revascularization in patients requiring emergent LMCA intervention. This demonstrates that PCI was associated with better in-hospital and follow-up outcomes than CABG, especially in patients presented in critically ill conditions. This supports PCI as the intervention of choice for hemodynamically unstable patients in the setting of myocardial infarction. However, the study had some limitations, including its retrospective, nonrandomized design and the potential influence of unmeasured factors, such as the surgeons' experience and the volumes of the procedures at participating centers. Therefore, future randomized trials on this subset of patients are highly recommended to continue to define optimal revascularization strategies.

Conclusions

Emergent LMCA revascularization is associated with high in-hospital mortality and morbidity. Nevertheless, patients who survive to discharge have a much better prognosis. PCI could be advantageous over CABG in revascularizing LMCA disease in emergencies. PCI could be preferred for revascularization of non-emergent LMCA in patients with intermediate EuroSCORE and low and intermediate SYNTAX scores.

Acknowledgements

The authors would like to thank all the nurses and cardiac catheterization technologists who helped in collecting the data from all the participating centers.

Declarations

This study was approved by the Institutional Review Board of King Faisal Specialist Hospital and Research Center in Riyadh (12 November 2020—RAC # 2201226: Gulf-LM Registry) and was carried out per the local guidelines and ethical guidelines of the Declaration of Helsinki.
The IRB waived informed consent for this study due to its retrospective and observational nature and the absence of any patient-identifying information.

Competing interests

The authors declare that they have no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Gaudino M, Farkouh ME, Stone GW. Left main revascularization: an evidence-based reconciliation. Eur Heart J. 2022;43(25):2421–4.CrossRefPubMed Gaudino M, Farkouh ME, Stone GW. Left main revascularization: an evidence-based reconciliation. Eur Heart J. 2022;43(25):2421–4.CrossRefPubMed
4.
Zurück zum Zitat Huang HW, Brent BN, Shaw RE. Trends in percutaneous versus surgical revascularization of unprotected left main coronary stenosis in the drug-eluting stent era: a report from the American college of cardiology-national cardiovascular data registry (ACC-NCDR). Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2006;68(6):867–72.CrossRef Huang HW, Brent BN, Shaw RE. Trends in percutaneous versus surgical revascularization of unprotected left main coronary stenosis in the drug-eluting stent era: a report from the American college of cardiology-national cardiovascular data registry (ACC-NCDR). Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2006;68(6):867–72.CrossRef
5.
Zurück zum Zitat Tam DY, Fang J, Rocha RV, Rao SV, Dzavik V, Lawton J, et al. Real-world examination of revascularization strategies for left main coronary disease in ontario. Canada JACC Cardiovasc Interv. 2023;16(3):277–88.CrossRefPubMed Tam DY, Fang J, Rocha RV, Rao SV, Dzavik V, Lawton J, et al. Real-world examination of revascularization strategies for left main coronary disease in ontario. Canada JACC Cardiovasc Interv. 2023;16(3):277–88.CrossRefPubMed
6.
Zurück zum Zitat Daoulah A, Alasmari A, Hersi AS, Alshehri M, Al GT, Abuelatta R, et al. Percutaneous coronary intervention Vs coronary artery bypass surgery for unprotected left main coronary disease: G-LM registry. Curr Probl Cardiol. 2022;47(10):101002.CrossRefPubMed Daoulah A, Alasmari A, Hersi AS, Alshehri M, Al GT, Abuelatta R, et al. Percutaneous coronary intervention Vs coronary artery bypass surgery for unprotected left main coronary disease: G-LM registry. Curr Probl Cardiol. 2022;47(10):101002.CrossRefPubMed
7.
Zurück zum Zitat Daoulah A, Abozenah M, Alshehri M, Hersi AS, Yousif N, Al GT, et al. Unprotected left main revascularization in the setting of non-coronary atherosclerosis: gulf left main registry. Curr Probl Cardiol. 2023;48(1):101424.CrossRefPubMed Daoulah A, Abozenah M, Alshehri M, Hersi AS, Yousif N, Al GT, et al. Unprotected left main revascularization in the setting of non-coronary atherosclerosis: gulf left main registry. Curr Probl Cardiol. 2023;48(1):101424.CrossRefPubMed
9.
Zurück zum Zitat Ong ATL, Serruys PW, Mohr FW, Morice M-C, Kappetein AP, Holmes DRJ, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J. 2006;151(6):1194–204.CrossRefPubMed Ong ATL, Serruys PW, Mohr FW, Morice M-C, Kappetein AP, Holmes DRJ, et al. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J. 2006;151(6):1194–204.CrossRefPubMed
10.
Zurück zum Zitat Medina A, Suárez de Lezo J, Pan M. A new classification of coronary bifurcation lesions. Rev Esp Cardiol. 2006;59:183.CrossRefPubMed Medina A, Suárez de Lezo J, Pan M. A new classification of coronary bifurcation lesions. Rev Esp Cardiol. 2006;59:183.CrossRefPubMed
11.
Zurück zum Zitat Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–4.CrossRefPubMed Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010;8(1):202–4.CrossRefPubMed
12.
Zurück zum Zitat Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.CrossRefPubMed Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.CrossRefPubMed
13.
Zurück zum Zitat Ballantyne A, Eriksson S. Research ethics revised: the new CIOMS guidelines and the world medical association declaration of helsinki in context. Bioethics. 2019;33:310–1.CrossRefPubMed Ballantyne A, Eriksson S. Research ethics revised: the new CIOMS guidelines and the world medical association declaration of helsinki in context. Bioethics. 2019;33:310–1.CrossRefPubMed
14.
Zurück zum Zitat Abdelmalak HD, Omar HR, Mangar D, Camporesi EM. Unprotected left main coronary stenting as alternative therapy to coronary bypass surgery in high surgical risk acute coronary syndrome patients. Ther Adv Cardiovasc Dis. 2013;7(4):214–23.CrossRefPubMed Abdelmalak HD, Omar HR, Mangar D, Camporesi EM. Unprotected left main coronary stenting as alternative therapy to coronary bypass surgery in high surgical risk acute coronary syndrome patients. Ther Adv Cardiovasc Dis. 2013;7(4):214–23.CrossRefPubMed
15.
Zurück zum Zitat Tam DY, Bakaeen F, Feldman DN, Kolh P, Lanza GA, Ruel M, et al. Modality selection for the revascularization of left main disease. Can J Cardiol. 2019;35(8):983–92.CrossRefPubMed Tam DY, Bakaeen F, Feldman DN, Kolh P, Lanza GA, Ruel M, et al. Modality selection for the revascularization of left main disease. Can J Cardiol. 2019;35(8):983–92.CrossRefPubMed
17.
Zurück zum Zitat Baek JY, Seo SM, Park H-J, Kim PJ, Park MW, Koh YS, et al. Clinical outcomes and predictors of unprotected left main stem culprit lesions in patients with acute ST segment elevation myocardial infarction. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2014;83(7):E243–50.CrossRef Baek JY, Seo SM, Park H-J, Kim PJ, Park MW, Koh YS, et al. Clinical outcomes and predictors of unprotected left main stem culprit lesions in patients with acute ST segment elevation myocardial infarction. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2014;83(7):E243–50.CrossRef
18.
Zurück zum Zitat Cheng C-I, Wu C-J, Fang C-Y, Youssef AA, Chen C-J, Chen S-M, et al. Feasibility and safety of transradial stenting for unprotected left main coronary artery stenoses. Circ J. 2007;71(6):855–61.CrossRefPubMed Cheng C-I, Wu C-J, Fang C-Y, Youssef AA, Chen C-J, Chen S-M, et al. Feasibility and safety of transradial stenting for unprotected left main coronary artery stenoses. Circ J. 2007;71(6):855–61.CrossRefPubMed
19.
Zurück zum Zitat Vis MM, Beijk MA, Grundeken MJ, Baan JJ, Koch KT, Wykrzykowska JJ, et al. A systematic review and meta-analysis on primary percutaneous coronary intervention of an unprotected left main coronary artery culprit lesion in the setting of acute myocardial infarction. JACC Cardiovasc Interv. 2013;6(4):317–24.CrossRefPubMed Vis MM, Beijk MA, Grundeken MJ, Baan JJ, Koch KT, Wykrzykowska JJ, et al. A systematic review and meta-analysis on primary percutaneous coronary intervention of an unprotected left main coronary artery culprit lesion in the setting of acute myocardial infarction. JACC Cardiovasc Interv. 2013;6(4):317–24.CrossRefPubMed
20.
Zurück zum Zitat Nagaoka H, Ohnuki M, Hirooka K, Shimoyama T. Emergency coronary artery bypass grafting for left main coronary artery disease. Kyobu Geka. 1999;52(8 Suppl):634–8.PubMed Nagaoka H, Ohnuki M, Hirooka K, Shimoyama T. Emergency coronary artery bypass grafting for left main coronary artery disease. Kyobu Geka. 1999;52(8 Suppl):634–8.PubMed
21.
Zurück zum Zitat Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341(9):625–34.CrossRefPubMed Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341(9):625–34.CrossRefPubMed
22.
Zurück zum Zitat Fernando SM, Price S, Mathew R, Slutsky AS, Combes A, Brodie D. Mechanical circulatory support in the treatment of cardiogenic shock. Curr Opin Crit Care. 2022;28(4):434–41.CrossRefPubMed Fernando SM, Price S, Mathew R, Slutsky AS, Combes A, Brodie D. Mechanical circulatory support in the treatment of cardiogenic shock. Curr Opin Crit Care. 2022;28(4):434–41.CrossRefPubMed
23.
Zurück zum Zitat Pappalardo A, Mamas MA, Imola F, Ramazzotti V, Manzoli A, Prati F, et al. Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2011;4(6):618–26.CrossRefPubMed Pappalardo A, Mamas MA, Imola F, Ramazzotti V, Manzoli A, Prati F, et al. Percutaneous coronary intervention of unprotected left main coronary artery disease as culprit lesion in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2011;4(6):618–26.CrossRefPubMed
Metadaten
Titel
Percutaneous coronary intervention vs. coronary artery bypass grafting in emergency and non-emergency unprotected left-main revascularization
verfasst von
Amin Daoulah
Abdulrahman H. Alqahtani
Ahmed Elmahrouk
Nooraldaem Yousif
Wael Almahmeed
Amr A. Arafat
Turki Al Garni
Mohammed A. Qutub
Ziad Dahdouh
Mohammed Alshehri
Ahmad S. Hersi
Majed M. Malak
Syifa R. Djunaedi
Ayesha Zaidi
Maryam Jameel Naser
Wael Qenawi
Abdelmaksoud Elganady
Taher Hassan
Vincent Ball
Youssef Elmahrouk
Adnan Fathey Hussien
Badr Alzahrani
Reda Abuelatta
Ehab Selim
Ahmed Jamjoom
Khalid Z. Alshali
Shahrukh Hashmani
Wael Refaat
Hameedullah M. Kazim
Mohamed Ajaz Ghani
Haitham Amin
Ahmed M. Ibrahim
Abdulwali Abohasan
Mohamed N. Alama
Mohammed Balghith
Ibrahim A. M. Abdulhabeeb
Osama Ahmad
Mohamed Ramadan
Ahmed A. Ghonim
Abeer M. Shawky
Husam A. Noor
Abdulrahman M. Alqahtani
Faisal Al Samadi
Seraj Abualnaja
Rasha Taha Baqais
Abdulkarim Alhassoun
Issam Altnji
Mushira Khan
Abdulaziz Alasmari
Alwaleed Aljohar
Niranjan Hiremath
Jairam Aithal
Amir Lotfi
Publikationsdatum
01.12.2023
Verlag
BioMed Central
Erschienen in
European Journal of Medical Research / Ausgabe 1/2023
Elektronische ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01189-1

Weitere Artikel der Ausgabe 1/2023

European Journal of Medical Research 1/2023 Zur Ausgabe